O
Oto
Builds digital therapy apps for overlooked and underserved chronic conditions
About Oto
Oto is a digital health startup that offers a unique, personalized coaching program for individuals suffering from tinnitus, a condition characterized by a constant ringing or noise in the ears. The company's primary market is tinnitus sufferers who are seeking effective, scientifically-backed therapies to manage their condition.
Oto's business model revolves around providing a step-by-step approach to therapy, combining the expertise of award-winning hearing therapist and audiologist Anna Pugh, ENT consultant and leading hearing researcher Jameel Muzaffar, and co-founder Dr. George Leidig, who himself has personal experience with tinnitus. This team has over 30 years of experience in the field and is committed to delivering ongoing, holistic support to their users.
The company's therapy program includes Cognitive Behavioural Therapy (CBT) sessions, which have been credited by users for making a significant difference in their recovery. The program also equips users with tools and techniques that they can rely on to manage their tinnitus independently in the long term.
Oto generates revenue by charging users for access to its personalized therapy program. The company's value proposition lies in its ability to offer a unique, effective, and accessible solution to tinnitus sufferers, a market that is often underserved by traditional healthcare providers.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Milton Keynes, United Kingdom
- Employees
- 24
- Open positions
- None listed
- Dealroom signal
- 83.5/100
- Industry
- Health, Wellness Beauty
- Sub-industry
- Health Platform
- Sector
- Health Tech & Medtech, Hearing, Chronic Disease, Sustainable Development Goals, Digital Therapeutics, Tech for Patients, Hard Tech, Digital Care, YC W22
- Technology
- Mobile app
- Business model
- SaaS
- Client focus
- b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | Jul 2022 | $3.7M | $15M | Octopus Ventures · Y Combinator · Goodwater Capital · Bethnal Green Ventures (BGV) | ↗ |
| SEED✓Equity / VC | Mar 2022 | $125K | $500K | Y Combinator | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Oto is 12K monthly website visits, up 110.5% over the last three months. Oto's team grew 20% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed11 investors entered at this stage
Bethnal Green Ventures (BGV)
Errol Damelin
Acequia Capital
West Midlands Academic Health Science Network
Matt Robinson
Simon Franks
Y Combinator
Calm/Storm Ventures
Ian Hogarth
Octopus Ventures
Goodwater Capital
Other known investors2 additional known investors
RYSE Asset Management
Thomas D.
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Oto on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Oto’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.